ImmunityBio (IBRX) Operating Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Operating Expenses data on file, last reported at $114.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 40.83% year-over-year to $114.0 million in Q1 2026; TTM through Mar 2026 was $402.4 million, a 16.75% increase from a year earlier, with the FY2025 full-year figure at $369.3 million, up 2.89% from the prior year.
• Operating Expenses for Q1 2026 stood at $114.0 million, up from $103.0 million in the prior quarter.
• Over the last five years, Operating Expenses for IBRX reached as high as $114.0 million in Q1 2026 and fell as low as $77.0 million in Q4 2024.
• Historically, Operating Expenses has averaged $91.6 million across 5 years, with a median of $87.7 million in 2025.
• Across the five-year window, Operating Expenses fell 15.0% in 2025 and soared 40.83% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $85.0 million in 2022, then increased by 0.65% to $85.5 million in 2023, then decreased by 10.03% to $77.0 million in 2024, then surged by 33.81% to $103.0 million in 2025, then gained by 10.71% to $114.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $114.0 million in Q1 2026, $103.0 million in Q4 2025, and $87.7 million in Q3 2025.